PHARMANEXT
ActiveSummary
The computed 12-month bankruptcy probability of PHARMANEXT is 2.1% (moderate). The 2025 annual accounts show equity of €531,183 and a net result of €169,596. Equity is growing by about 33% per year across the filed financial years. Its solvency ranks better than 34% of 12,397 sector peers (NACE 47, financial year 2025). The company has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Owners and capital
Owners
2 ownersChain of control
- BLUESTONE
- PHARMANEXT
Highest known parent: BLUESTONE. The sources do not say who stands above it.
Owners 2
- BLUESTONEparentSourceaccounts BLUESTONE 202580%
-
20%
According to the 2025 annual accounts of PHARMANEXT and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.